Frequency Therapeutics cuts 30% of workforce, appoints new CFO

Korro Bio, Inc.

Workforce reduction of ~30% to focus capital on FX-322, FX-345, and MS program.
Estimated $1.2M in future cash severance costs; majority implemented, remainder by July 31, 2022.
Richard M. Mitrano appointed principal financial officer, succeeding Peter P. Pfreundschuh.
Mitrano previously Vice President of Finance and Operations since July 2016.

item 2.05 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter P. Pfreundschuh

Chief Financial Officer

KRRO · Korro Bio, Inc.

Effective: 2022-04-05
Successor: Richard M. Mitrano
Filed: April 8, 2022, 7:59 PM ET

On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer, succeeding Peter P. Pfreundschuh, the Company’s former Chief Financial Officer.

Appointed

Richard M. Mitrano

principal financial officer and principal accounting officer

KRRO · Korro Bio, Inc.

Effective: 2022-04-05
Filed: April 8, 2022, 7:59 PM ET

On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..

Action: succeeded
Role: Chief Financial Officer

Exact text from the filing

On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer, succeeding Peter P. Pfreundschuh, the Company’s former Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Richard M. Mitrano was appointed as principal financial officer and principal accounting officer at Korro Bio, Inc..

Action: appointed
Role: principal financial officer and principal accounting officer

Exact text from the filing

On April 5, 2022, the Board appointed Richard M. Mitrano, the Company’s Vice President of Finance and Operations, as the Company’s principal financial officer and principal accounting officer

View on SEC.gov

Korro Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-100522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.